St Vincent’s Professor Louise Emmett to co-lead landmark MRFF $18M funded study
St Vincent’s is proud to be part of a ground-breaking national research initiative to transform care for men with advanced prostate cancer. With $18 million in Federal funding from the Medical Research Future Fund (MRFF), this program will fast-track a new targeted alpha therapy – a next-generation treatment using world-first radiopharmaceutical technology. Our very own Professor Louise Emmett is co-leading the clinical trials, drawing on St Vincent’s long-standing commitment to innovation in nuclear medicine and patient-centred research.
This collaboration gives us the tools to explore smarter, more effective treatments for prostate cancer – using targeted alpha therapy to help patients live longer, better lives.
A new $18 million initiative is taking on the fight – with world-first technology and world-leading collaboration. St Vincent’s Prof Louise Emmett is among the lead investigators driving this life-changing research.
AdvanCell has received $18m in Federal funding from the Medical Research Future Fund (MRFF) to help transform the clinical management of metastatic prostate cancer by combining cutting-edge radiopharmaceutical technology with cellular biology expertise to improve patient outcomes.
This initiative brings together leading experts from across Australia, from institutions including the Peter MacCallum Cancer Centre, the University of Sydney, and AdvanCell.
Among them is St Vincent’s Professor Louise Emmett, who is co-leading the clinical research and biomarker study to fast-track translation of this therapy into patient care.
Prof Emmett’s work will help transform how metastatic prostate cancer is diagnosed and treated, aiming to improve survival and quality of life for men across the country.
Key Statistics:
- One in eight Australian men will face prostate cancer in their lifetime.